117 related articles for article (PubMed ID: 34315006)
1. Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer.
Kim SY; Kim K; Cho SH; Chun SM; Tak E; Hong YS; Kim JE; Kim TW
Cancer Genet; 2021 Nov; 258-259():27-36. PubMed ID: 34315006
[TBL] [Abstract][Full Text] [Related]
2.
Ye S; Hu X; Ni C; Jin W; Xu Y; Chang L; Zhou H; Jiang J; Yang L
Mol Cancer Ther; 2020 Mar; 19(3):956-965. PubMed ID: 31924740
[TBL] [Abstract][Full Text] [Related]
3.
Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
[No Abstract] [Full Text] [Related]
4. Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Stahler A; Heinemann V; Holch JW; von Einem JC; Westphalen CB; Heinrich K; Schlieker L; Jelas I; Alig AHS; Fischer LE; Weiss L; Modest DP; von Weikersthal LF; Decker T; Kiani A; Moehler M; Kaiser F; Kirchner T; Jung A; Stintzing S
Int J Cancer; 2021 Dec; 149(11):1935-1943. PubMed ID: 34310714
[TBL] [Abstract][Full Text] [Related]
5. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
Lin JK; Lin AJ; Lin CC; Lan YT; Yang SH; Li AF; Chang SC
J Surg Oncol; 2011 Nov; 104(6):661-6. PubMed ID: 21671463
[TBL] [Abstract][Full Text] [Related]
6. Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes.
Manzanares-Martin B; Cebrián Aranda A; Del Puerto-Nevado L; González R; Solanes S; Gómez-España MA; García-Foncillas J; Aranda E
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833048
[TBL] [Abstract][Full Text] [Related]
7. HER2
Gharib E; Salmanipour R; Nazemalhosseini Mojarad E; Yaghoob Taleghani M; Sarlak S; Malekzade-Moghani M; Nasrabadi PN; Meiary MA; Asadzadeh Aghdaei H; Zali MR
J Cell Physiol; 2019 Aug; 234(8):13137-13144. PubMed ID: 30549033
[TBL] [Abstract][Full Text] [Related]
8. New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients.
Jing C; Wang T; Ma R; Cao H; Wang Z; Liu S; Chen D; Zhang J; Wu Y; Zhang Y; Wu J; Feng J
Mol Carcinog; 2020 May; 59(5):478-491. PubMed ID: 32141150
[TBL] [Abstract][Full Text] [Related]
9. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
Borrero-Palacios A; Cebrián A; Gómez Del Pulgar MT; García-Carbonero R; Garcia-Alfonso P; Aranda E; Elez E; López-López R; Cervantes A; Valladares M; Nadal C; Viéitez JM; Guillén-Ponce C; Rodríguez J; Hernández I; García JL; Vega-Bravo R; Puime-Otin A; Martínez-Useros J; Del Puerto-Nevado L; Rincón R; Rodríguez-Remírez M; Rojo F; García-Foncillas J
Sci Rep; 2019 Feb; 9(1):2589. PubMed ID: 30796344
[TBL] [Abstract][Full Text] [Related]
10. Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).
García-Albéniz X; Alonso V; Escudero P; Méndez M; Gallego J; Rodríguez JR; Salud A; Fernández-Plana J; Manzano H; Zanui M; Falcó E; Feliu J; Gil M; Fernández-Martos C; Bohn U; Alonso C; Calderero V; Rojo F; Cuatrecasas M; Maurel J
Oncologist; 2019 Nov; 24(11):e1115-e1122. PubMed ID: 31235483
[TBL] [Abstract][Full Text] [Related]
11. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
[TBL] [Abstract][Full Text] [Related]
12. EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer.
Birkman EM; Avoranta T; Ålgars A; Korkeila E; Lintunen M; Lahtinen L; Kuopio T; Ristamäki R; Carpén O; Sundström J
Hum Pathol; 2018 Dec; 82():163-171. PubMed ID: 30096327
[TBL] [Abstract][Full Text] [Related]
13. The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer.
Khelwatty S; Essapen S; Bagwan I; Green M; Seddon A; Modjtahedi H
Oncotarget; 2017 Jan; 8(5):7666-7677. PubMed ID: 28032593
[TBL] [Abstract][Full Text] [Related]
14. Amphiregulin Expression Is a Predictive Biomarker for
Stahler A; Stintzing S; Modest DP; Ricard I; Giessen-Jung C; Kapaun C; Ivanova B; Kaiser F; Fischer von Weikersthal L; Moosmann N; Schalhorn A; Stauch M; Kiani A; Held S; Decker T; Moehler M; Neumann J; Kirchner T; Jung A; Heinemann V
Clin Cancer Res; 2020 Dec; 26(24):6559-6567. PubMed ID: 32943459
[TBL] [Abstract][Full Text] [Related]
15. Use of a High-Throughput Genotyping Platform (OncoMap) for
Kim D; Hong YS; Kim JE; Kim KP; Lee JL; Chun SM; Kim J; Jang SJ; Kim TW
Cancer Res Treat; 2017 Jan; 49(1):37-43. PubMed ID: 27121720
[TBL] [Abstract][Full Text] [Related]
16. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
[TBL] [Abstract][Full Text] [Related]
17. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
[TBL] [Abstract][Full Text] [Related]
18. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M
Oncotarget; 2017 May; 8(21):35289-35300. PubMed ID: 27852040
[TBL] [Abstract][Full Text] [Related]
19. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
20. NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction.
Li W; Qiu T; Guo L; Ying J; Zhou A
Pathol Res Pract; 2019 Mar; 215(3):483-489. PubMed ID: 30611619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
